Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Nociceptin (HB2424)
Description:Endogenous NOP agonist. Involved in a variety of physiological processes.
Orexin A (human, rat, mouse) (HB2937)
Description:Excitatory neuropeptide at orexin OX1/OX2 receptors
Recombinant human Artemin protein (HB8222)
Description:Neurotrophic factor from the GDNF family ligands
- Description:
HEK expressed recombinant human BDNF protein
- Description:
His tag recombinant human BDNF protein
- Description:
CHO-expressed recombinant human beta-NGF protein
Recombinant human beta-NGF protein (HB9303)
Description:Neurotrophic factor related to BDNF, NT-3 and NT-4